Nucleic Acid Testing for HIV-1 Diagnosis and Monitoring by Ricardo Sobhie Diaz
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Nucleic Acid Testing for HIV-1 
Diagnosis and Monitoring 
Ricardo Sobhie Diaz 
Retrovirology Laboratory Infectious Diseases Division, Paulista School of Medicine, 




In the test and treat era of HIV-1 epidemics, it is becoming extremely urgent to detected 
HIV-1 infected individuals. It is well known that HIV-1 testing enables health care 
professions to strategize interventions towards interruption of HIV-1 transmission chains, 
and to implement antiretroviral therapy. Expanding the number of persons treated with 
antiretroviral potentially decrease the number of new infections.[1] It is very well 
determined that the available antibodies based assays are very effective in the majority of 
cases to detect and confirm HIV-1 infection. However, some exceptions do apply. Diagnosis 
of HIV-1 infection during the so-called immunologic window period, which is the time 
between the acquisition of HIV infection and the HIV antibody detection, may be of 
fundamental importance in some specific cases. It has been debated that effective 
antiretroviral treatment instituted during acute infection period, which occurs during the 
immunologic window period, may contribute to a better restructuration of the host immune 
system, thus allowing to a better long term virologic control or to slower pace of disease 
progression.[2] Detection of infections during the immunologic window period is also a 
necessity in order to increase the safety of the blood supply. Furthermore, detection of HIV-
1 infection is not specific enough in the cases where the passive transfer of antibodies occurs, 
such as among infants born from HIV infected mothers. For all these above applications, the 
direct identification of the pathogen can be an extremely helpful tool, which can be 
performed using molecular biology based techniques. It is important to bear in mind that 
passive transfer of antibodies do not occur exclusively among infant born from HIV positive 
mothers. In one case, a blood recipient from a seropositive unit did not get infected by HIV, 
but received antibodies that made anti HIV-EIA and Western-blot positive for a period up to 
six month, being the western blot profile identical to the one found in the infected blood 
donor.[3] Other case also showed the immediate detection of donors anti-HIV antibodies 
following a health care work accident, where a broken blood collection tube injured a 
nurse.[4]   
Molecular based techniques area also present in the HIV monitoring tools in tests known as 
viral load assays. Viral load monitoring can classically predict the pace of HIV-1 disease 
progression[5] and the effectiveness of antiretroviral treatment. Those tests are still evolving 
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and becoming more sensitive, since detection of low level residual replication is becoming 
increasingly important in the management of HIV-1 infected individuals. Furthermore, 
molecular biology has been applied as a valuable tool in detection of HIV strains resistant to 
antiretrovirals. It is no longer acceptable empirical change in antiretroviral treatment since 
resistance testing can increase the odds of a successful salvage therapy.[6, 7]  As treatment 
evolves, laboratory tests emerge to make any kind of treatment more effective, safe and 
predictable. It is the pharmacogenomics playing its role, and again, based in molecular 
biology techniques. This chapter will describe the challenges related to HIV diagnosis and 
monitoring, and the contribution of molecular tests in this field. 
2. Nucleic acid testing and diagnosis of primary HIV infection 
a. Early stages of HIV Infection 
After an exposure to HIV-1, and in spite of the exposition route, a dendritic cell will capture 
the virus and conduct it to the regional lymphonode with the intention of constructing the 
adaptative immune response.[8]  Odds of becoming HIV infected relates to the viral load of 
the donor of the infection in spite of the rout of HIV transmission. Studies show that there is 
a threshold level of viral load bellow which heteroseuxual transmission is unlikely to 
occur.[9, 10]  The level of viremia in a blood donor at the time of the donation is the primary 
factor influencing the probability of the infection.[11] A similar relationship between viral 
load and HIV transmission has been proposed for perinatal and[12] needlestick 
exposures.[13, 14] Interestingly however, HIV-1 transmission is considered to be clonal in 
the large majority of the cases, since 76% start from a single transmitted HIV strains and in 
24% of the cases, transmission is seeded by two to five HIV strains.[15]  The burst of viremia 
will start after the dendritic cells reach the regional lymphonode, which takes from 5 to 14 
days.[16]   Dendridic cells do not get infected by HIV, and after attachment to the DC-SIGN, 
these cells captures the virus and bring it trapped in its surface or even protected by 
endocitosis in its way to the regional lymphonode (the dendritic cell present in the genital 
mucosa is the Langherhan cell). The time elapsed between HIV exposure and the burst of 
viremia is denominated eclipse period.[17]   
When viral replication starts, HIV-1 viral load tends to be exceedingly high, usually with the 
detection of more than 1 million of HIV RNA copies/mL.[17]  Once host immune specific 
humoral and cellular immunity starts to emerge, viral load tends to decrease to basal values 
which tend to be constant for the rest for life, and usually affected only by antiretroviral 
treatment.  
Third generation HIV EIA tests can detected HIV as early as 1 month after exposure, and 
time elapsed between the exposure to HIV and detection of specific antibodies are described 
as the immunologic window period (Figure 1). The first HIV marker that can be detected is 
the RNA of virions, which occurs after 17 days (13 to 28), followed by the proviral DNA at 
the 20th day (18 to 34), followed by the detection of the p24 antigen, which occurs at day 22 
(18 to 34).[17]  All those markers can be readily used to shorten up the period to detect HIV-
1 infection after the exposure event. 
b. Nucleic acid testing during the immunologic window period. 
The diagnosis of HIV infection is challenging in individuals with recent exposure or 
symptomatic primary infection, and or the detection of HIV infection from mother to child 
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Fig. 1. Approximately sequence and time course of virological and serological events during 
primary HIV-1 infection. Plasma HIV-1 RNA is detected by commercial viral load assays, 
whereas HIV DNA in PBMCs is detected by home brew PCE assays.[17]   
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after vertical exposure. Either of the above mentioned tests, the virion RNA, proviral DNA 
and p24 antigen can be of utility in the detection of HIV infection after the eclipse period 
and before fully HIV-1 seroconversion. Especially challenging is the diagnosis among 
children born from infected mothers. All those children will receive a passive transfer of 
maternal antibodies which can make anti HIV results positive for up t 18 month after 
delivery.[18] It is known that the great majority of exposed children will not become HIV 
infected. Without any sort of antiretroviral prophylaxis, which include the treatment of the 
mother and use of anitretrovirals by the exposed children for a limited time period, only 20 
to 30% of exposed children will become infected.[19] Incident infections will follow to 7% 
with the use of zidovudine monotherapy by the mothers,[18] being even 50% more 
efficacious with the use of single doses nevirapine by the time of delivery[20] and to 
virtually zero if highly active antiretroviral therapy is successfully used, and maintaining 
maternal viral loads bellow detection limits. Therefore, efforts to overcome the problem of 
low specificity in diagnosing HIV infection in newborns have been made targeting the direct 
identification of the virus. The first attempts to overcome this diagnostic problem have been 
made with the use of co-culture to detected HIV among newborns,[21] which is 
cumbersome, expensive, takes longer time, and requires well equipped laboratories that 
cannot be used in large scale in the clinical setting. Therefore, detection of HIV DNA and 
RNA seems to be more appropriate to detect the vertical transmission of HIV-1. 
Timing of vertical HIV transmission is also important in the strategy to test children born 
from infected mothers. A smaller and variable zproportion of HIV transmission will occur 
intra-uterus (around 30%), and in these cases, newborns will likely be viremic by the time of 
birth.[22]  In the peripartum transmission, however, the presence of viruses will occur in 
general around two weeks after birth.[23]  Other feature that needs to be taken into account 
relates to the viral dynamics of HIV- replication among children infected by the vertical 
route. Whereas among adults, viral load in general reaches the set point by 6 month after 
HIV infection,[24] and mean basal viral load is inferior to 100,000 RNA copies/mL, children 
will take much longer to show a week control of viremia after primary infection.[25]  In the 
case of infants, viral loads will be in general above 100,000 RNA copies/mL for a period that 
is superior to 24 month.[25]  
The use of RNA rather than proviral DNA for detection of primary infection has the 
advantage of providing a shorter window period between HIV acquisition and the first 
detectable virologic marker, as seen in Figure 1. False positive results with qualitative DNA 
PCR or quantitative RNA methodologies have been reported in the literature.[26-28]  
Usually the false positive result can be attributed to the Polymerase Chain reaction (PCR) 
carry over, decreasing specificity to as low as 96%.[26]  As an interesting example, transient 
HIV-1 infection has been proposed based on the detection of a positive PCR among children 
who seroreverted (HIV uninfected children born from HIV positive mothers who loose 
antibodies after 18 month of life).[29]  In these cases, detection of human HIV-1 on only one 
or a few occasions in these infants has been interpreted to indicate that infection may be 
transient rather than persistent. However, genetic analysis of viruses revealed that either 
specimens were mistakenly attributed to an infant, or phylogenetic analysis failed to 
demonstrate the expected linkage between the infant's and the mother's virus,[30] being 
PCR carry-over the likely explanation for these mistakes.  
PCR-carry over, which is a feature of molecular based tests that amplify nucleic acid targets, 
can be more difficult to be detected in qualitative rather than quantitative assays. In this 
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sense, viral load assays for detecting primary infection has the advantage of potentially 
discriminating false positive results due to PCR carry over from true positive results since it 
is expected a high viral load in these situations, being this particularly true for children born 
from infected mother. In other words, a qualitative assay gives a “yes” or “no” result, 
whereas the viral load assays can potentially discriminate false positive results since it is 
expected a very high viral load during primary HIV infection or in infection among children 
with less than two years old. It has to be taken into account that PCR carry over will always 
provide a considerable low viral load, which usually is low than 1,000 RNA copies/mL. 
Therefore, as discussed above, better tests to detect HIV infection in these target populations 
are assays that targets RNA rather than DNA, and have the quantitative nature rather than 
qualitative, those tests being the RNA viral load assays. When those tests are performed in 
children using samples collected after 3 weeks of deliver, the sensitivity, specificity, positive 
and negative predictive value can be all 100%.[23]   
c. HIV-1 RNA quantitation for HIV-1 infection monitoring (ultra-sensitive) 
It has been defined since the beginning of the HIV epidemics that HIV-1 viral replication 
relates well with disease progression and response to treatment.[5]  The guidelines for HIV 
treatment recommend that viral load should be kept as low as possible, preferable bellow 
detection levels. However, questions have been always related to how sensitive should be a 
viral load assays. It has been demonstrated that viral replication will occur in spite of the 
apparently complete HIV suppression using antiretrovirals. One cohort of 130 treated 
patients kept of HIV-1 RNA viral load bellow 75 copies/mL revealed that 80% of 
individuals will still present detectable viremia when more sensitive viral load strategies 
were used (1 RNA copies/mL of plasma) being the median viral load equal 3.1 
copies/mL.[31, 32]  Other study showed that this low level viremia is likely to be shed by 
the gastrointestinal tract sanctuary.[33] It has been described that this low level (and 
sometimes unrecognized) viral replication may lead to a CD4 and CD8+ T cell activation 
which relates to relates to apoptosis and disease progression.[34, 35]  This cell activation can 
be also detected among elite suppressors, which are individuals that naturally control 
viremia thus preventing the CD4+ T cell decline, and this cell activation may relate to 
deleterious aspects among those individuals.[36, 37] 
The risk of selecting HIV-1 antiretroviral resistant strains also relates to the level of viral 
replication, and the pace of emergence of resistant related mutations may be somewhat 
predictable. Indeed, the number of new mutations relates to the residual viral replication, 
being directly proportional to the viral load of individuals in virologic failure.[38] 
d. HIV-1 antiretrovirals resistance testing  
It has been recognized that HIV resistance testing is of benefit in the performance of salvage 
therapy[7, 31, 39-41] and survival rates.[42]  Furthermore, resistant testing exerts great 
influence in medical decision regarding choice of antiretrovirals in salvage therapy.[43]  The 
current available resistance testing are the so called genotypic resistance tests. Those are 
indirect measures of resistance, where HIV RNA is obtained, reverse transcribed and cDNA 
is sequenced to detect the antiretroviral related mutations. Interpretation algorithms are 
applied to infer the activity of diverse antiretroviral agents. The direct measure of resistance 
is provided by the phenotypic assays. In these assays, RNA form HIV is also purified and 
recombinant viruses that have the pol gene of patient´s HIV and the backbone of a 
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laboratory virus are produced in vitro. These pseudoviruses are cultured with different 
concentrations of different antiretrovirals and the resistant related fold change is 
determined. Fold changes always refer to the amount of drug used to inhibit the patient´s 
HIV compared to the wild type laboratory strain. Biological and clinical cut-offs are used to 
infer the probability of response to specific antiretrovirals. Genotypic tests are easier to 
perform, more available and less expensive than phenotypic based assays. They also are 
more sensitive in detecting resistance when mixtures of mutant and wild type viruses are 
present, since it is likely that resistant strains will be overwhelmed by the more fit wild type 
strains in the initial culture producing the pseudoviruses.[44]  The quantitative nature of 
phenotypic based assays may be of utility in analyzing the highly resistance strains. 
Phenotypic tests are also advantageous for new antiretrovirals with poorly defined 
resistance profile and perhaps for non-B strains, where resistance pathways and mutations 
may not be yet available. Furthermore, the presence of fold change and clinical cut-off 
increase the confidence of physicians in the choice of salvage therapy.[43]  There is also the 
virtual phenotype test, which is in fact a genotypic based assays. In these tests, HIV-1 pol 
sequences are submitted to a specific database, which will infer the phenotypic profile of 
viruses providing fold changes and clinical cut-offs. In fact, performance of virtual 
phenotype has been comparable or better than the performance found using phenotype for 
salvage therapy.[41, 45] The likely explanation for the alleged better performance of virtual 
phenotype as compared to the “real” phenotype relies in the fact that virtual phenotype will 
be less likely to underestimate resistance since mixtures of wild type and resistant strains 
found in the sequencing process will be considered as resistant. Conversely, as explained 
above, mixtures of wild type/resistant will facilitate overgrow of wild type strains in cell 
culture.  
e. HIV-1 Tropism 
The practical issue of HIV-1 tropism emerged with the development of CCR5 antagonists 
as antiretrovirals. Nonetheless, HIV tropism has been studied for a long time in the 
attempt to correlate the HIV-1 correceptor use with cytopathycity. In summary, HIV may 
use CCR5 and CXCR4 chemokine receptors for entry, and viruses that exclusively use the 
CCR5 are denominated R5, viruses that use CXCR4 are X4, whereas viruses able to use 
both coreceptors are dual tropic (reviewed by Moore et al).[16]  Infection usually starts 
with R5 viruses and as HIV-1 quasispecies evolves, CXCR4 using strains may emerge. 
There is also the association between the emergence of CXCR4 using strains and rapid 
HIV-1 disease progression.[46] Therefore, it is conceivable that the determination and 
monitoring HIV-1 tropism over time may be of use in the decision of introduction of 
antiretroviral treatment or more frequent evaluation of CD4+ T cell levels in the infected 
patient.  
The main utility of tropism determination relates to the decision of use of CCR5 
antagonists such as maraviroc, since this specific class of antiretrovirals will lose activity 
in the presence of detectable X4 or dual tropic viruses.[47]  Therefore, a tropism test 
before treatment with these drugs is required; gold standard tropism tests being the 
phenotypic based tests. One phenotypic tropism test constructs pseudoviruses containing 
the gp160 of patient’s viruses and a backbone of HIV-1 laboratory virus plus the luciferase 
gene.[48] Two lineages of cells containing either the CCR5 or the CXCR4 coreceptors are 
used in two distinct lab reactions. Once infected, light will be generated from cells due the 
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presence of the luciferase gene, and HIV can be detected in the culture either inside cells 
harboring CCR5 and/or CXCR4 coreceptors. If HIV is detected only in the culture of cells 
harboring CCR5 coreceptor, viruses will be classified as R5, whereas X4 viruses will 
appear only in the culture of cells harboring CXCR4 coreceptors. In the case viruses are 
detected in both cultures, it is reported that dual mixed and/or mixtures of R5 and X4 are 
present. Alternatively, genotropism tests can be used. These tests detect substitutions at 
the V3 region of gp120 HIV-1 gene in order to predict the CXCR4 use by viruses present 
in the patient’s quaispecie. Although phenotypic and genotypic tests do not fully agree 
with each other, genotypic tests are probably equally able to predict virologic treatment 
failure in maraviroc containing antiretroviral schemes[47] and have been advocate as 
preferential in some guidelines.[49] 
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